Posted by Michael Wonder on 08 Jan 2018
Ionis' inotersen NDA accepted for priority review by the FDA
8 January 2018 - Ionis Pharmaceuticals announced today that its new drug application for inotersen has been accepted for priority review by the U.S. FDA.
Inotersen is an investigational drug for the treatment of patients with hereditary TTR amyloidosis (hATTR).
The FDA has set a Prescription Drug User Fee Act date of 6 July 2018.
